CT-P44 is currently being evaluated in an ongoing Phase 1/2 clinical trial (NCT04618371) in patients with advanced or metastatic solid tumors. The study aims to assess the safety, pharmacokinetics, and efficacy of CT-P44 as a single agent and in combination with other therapies.
is an investigational drug candidate developed by Celltrion . Based on publicly available information: ct-p44